Bandingkan Harga & Kinerja Minahasa Membangun Hebat Tbk. (HBAT) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Minahasa Membangun Hebat Tbk. dan Organon Pharma Indonesia Tbk.: Minahasa Membangun Hebat Tbk. diperdagangkan di Rp340 (kapitalisasi pasar 330,96 M, volume 24 jam 952,6 rb), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Minahasa Membangun Hebat Tbk. jauh lebih besar — sekitar 3,2× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| HBAT | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 330,96 M | 104,4 M |
Volume | 952,6 rb | — |
Lot | 9,53 rb | — |
Perputaran | 308,16 jt | — |
Harga Rata-rata | 323,49 | — |
Nilai Transaksi | 308,16 jt | — |
Harga Ekuilibrium Indikatif | 340 | — |
Volume Ekuilibrium Indikatif | 1,65 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Minahasa Membangun Hebat Tbk.
PT Minahasa Membangun Hebat Tbk was established based on Notarial Deed No. 44 datedJanuary 31, 2020 of Dian Fitriana, S.H., M.Kn., a public notary in Bekasi.
Selengkapnya di halaman HBAT →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
